Year in diabetes 2012: The diabetes tsunami
- PMID: 23185035
- PMCID: PMC3513534
- DOI: 10.1210/jc.2012-3487
Year in diabetes 2012: The diabetes tsunami
Abstract
Diabetes affects more than 300 million individuals globally, contributing to significant morbidity and mortality worldwide. As the incidence and prevalence of diabetes continue to escalate with the force of an approaching tsunami, it is imperative that we better define the biological mechanisms causing both obesity and diabetes and identify optimal prevention and treatment strategies that will enable a healthier environment and calmer waters. New guidelines from the American Diabetes Association/European Association of the Study of Diabetes and The Endocrine Society encourage individualized care for each patient with diabetes, both in the outpatient and inpatient setting. Recent data suggest that restoration of normal glucose metabolism in people with prediabetes may delay progression to type 2 diabetes (T2DM). However, several large clinical trials have underscored the limitations of current treatment options once T2DM has developed, particularly in obese children with the disease. Prospects for reversing new-onset type 1 diabetes also appear limited, although recent clinical trials indicate that immunotherapy can delay the loss of β-cell function, suggesting potential benefits if treatment is initiated earlier. Research demonstrating a role for the central nervous system in the development of obesity and T2DM, the identification of a new hormone that simulates some of the benefits of exercise, and the development of new β-cell imaging techniques may provide novel therapeutic targets and biomarkers of early diabetes detection for optimization of interventions. Today's message is that a diabetes tsunami is imminent, and the only way to minimize the damage is to create an early warning system and improve interventions to protect those in its path.
Figures
![Fig. 1.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/3513534/bin/zeg0121294980001.gif)
![Fig. 2.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/3513534/bin/zeg0121294980002.gif)
![Fig. 3.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/3513534/bin/zeg0121294980003.gif)
Similar articles
-
Management of hyperglycemia in hospitalized patients in non-critical care setting: an endocrine society clinical practice guideline.J Clin Endocrinol Metab. 2012 Jan;97(1):16-38. doi: 10.1210/jc.2011-2098. J Clin Endocrinol Metab. 2012. PMID: 22223765
-
ISPAD Clinical Practice Consensus Guidelines 2018: Type 2 diabetes mellitus in youth.Pediatr Diabetes. 2018 Oct;19 Suppl 27:28-46. doi: 10.1111/pedi.12719. Pediatr Diabetes. 2018. PMID: 29999228 No abstract available.
-
Current and Emerging Pharmacotherapies for Weight Management in Prediabetes and Diabetes.Can J Diabetes. 2015 Dec;39 Suppl 5:S134-41. doi: 10.1016/j.jcjd.2015.10.001. Can J Diabetes. 2015. PMID: 26654857 Review.
-
American Association of Clinical Endocrinologists, Associazione Medici Endocrinologi, and EuropeanThyroid Association Medical Guidelines for Clinical Practice for the Diagnosis and Management of Thyroid Nodules.Endocr Pract. 2010 May-Jun;16 Suppl 1:1-43. doi: 10.4158/10024.GL. Endocr Pract. 2010. PMID: 20497938 No abstract available.
-
Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.Pharmacoeconomics. 2004;22(6):389-411. doi: 10.2165/00019053-200422060-00005. Pharmacoeconomics. 2004. PMID: 15099124 Review.
Cited by
-
PRE1BRAZIL Protocol: A Randomized Controlled Trial to Evaluate the Effectiveness and Safety of the DPP-4 Inhibitor Alogliptin in Delaying the Progression of Stage 2 Type 1 Diabetes.Diabetes Metab Syndr Obes. 2024 Feb 21;17:857-864. doi: 10.2147/DMSO.S437635. eCollection 2024. Diabetes Metab Syndr Obes. 2024. PMID: 38406268 Free PMC article.
-
The Roles of Vitamins in Diabetic Retinopathy: A Narrative Review.J Clin Med. 2022 Nov 1;11(21):6490. doi: 10.3390/jcm11216490. J Clin Med. 2022. PMID: 36362717 Free PMC article. Review.
-
SERCA2a stimulation by istaroxime improves intracellular Ca2+ handling and diastolic dysfunction in a model of diabetic cardiomyopathy.Cardiovasc Res. 2022 Mar 16;118(4):1020-1032. doi: 10.1093/cvr/cvab123. Cardiovasc Res. 2022. PMID: 33792692 Free PMC article.
-
Synthesis, Optimization, and Biological Evaluation of Corrinated Conjugates of the GLP-1R Agonist Exendin-4.J Med Chem. 2021 Mar 25;64(6):3479-3492. doi: 10.1021/acs.jmedchem.1c00185. Epub 2021 Mar 6. J Med Chem. 2021. PMID: 33677970 Free PMC article.
-
Diabetes medications as potential calorie restriction mimetics-a focus on the alpha-glucosidase inhibitor acarbose.Geroscience. 2021 Jun;43(3):1123-1133. doi: 10.1007/s11357-020-00278-x. Epub 2020 Oct 2. Geroscience. 2021. PMID: 33006707 Free PMC article.
References
-
- Centers for Disease Control and Prevention 2011. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention
-
- World Health Organization 2011. World Health Organization: diabetes fact sheet. http://www.who.int/mediacentre/factsheets/fs312/en/index.html
-
- American Diabetes Association 2008. Economic costs of diabetes in the U.S. in 2007. Diabetes Care [Erratum (2008) 31:1271] 31:596–615 - PubMed
-
- Centers for Disease Control and Prevention 2012. Diabetes data and trends. Data from the National Health Interview Survey. Statistical analysis by the Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Division of Diabetes Translation. http://www.cdc.gov/diabetes/statistics/prev/national/figage.htm
-
- May AL, Kuklina EV, Yoon PW. 2012. Prevalence of cardiovascular disease risk factors among US adolescents, 1999–2008. Pediatrics 129:1035–1041 - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials